FDA panel recommends approval of Novo degludec insulin

By Ransdell Pierson (Reuters) – An advisory panel to the U.S. Food and Drug Administration on Thursday voted to recommend approval of Danish drugmaker Novo Nordisk’s new ...

POZEN Reports Third Quarter 2012 Financial Results and Positive PA32540 Clinical Updates

CHAPEL HILL, N.C.–(BUSINESS WIRE)– POZEN Inc. (POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the ...

Think Of Pfizer As A Cigarette Company

By Dana Blankenhorn Pfizer (PFE) is slowly becoming a cigarette stock. By that I mean Pfizer is not a growth stock, not something you buy based on stock price. You buy it based on ...

3 Stocks With High Alphas: Acadia, Hemispherx, And Vringo

By EnhydrisPECorp Speculating in the stock market can lead to either tremendous gains or calamitous results, often the latter. Any investor that lived through thedot-com bubble knows ...

Amicus Therapeutics Poised For Rebound Into December Phase III Results

By Mike Havrilla Amicus Therapeutics (FOLD) is focused on the development of new treatments for rare metabolic/genetic disorders, including lead product candidate AMIGAL (migalastat ...

ImmunoGen Is Living Life in the Fast Lane

By Sean Williams During election time, it’s not uncommon for some important newsworthy stories to get lost in the mix. One of those stories emerged Tuesday when ImmunoGen (Nasdaq: IMGN  ) ...

Sun Pharma to Acquire DUSA Pharmaceuticals, Inc.

WILMINGTON, Mass. and MUMBAI, India, Nov. 8, 2012 (GLOBE NEWSWIRE) — Sun Pharmaceutical Industries Limited ((Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715)) ...

UPDATE 2-FDA panel recommends approval of Novo degludec insulin

By Ransdell Pierson Nov 8 (Reuters) – An advisory panel to the U.S. Food and Drug Administration on Thursday voted to recommend approval of Danish drugmaker Novo Nordisk’s ...

Mylan To Wall Street: Forget Patent Cliff, We’ll Grow

By Marilyn Alva, Investor’s Business Daily Five years ago, Mylan (MYL) became the third-largest generic-drug company in the world, catapulted by two acquisitions totaling ...

Jazz Pharma Earnings Top Estimates As Xyrem Ramps

By Amy Reeves, Investor’s Business Daily Jazz Pharmaceuticals (JAZZ) beat analysts’ Q3 expectations late Thursday, though its accounting was complicated by recent mergers ...

Sanofi Halves Price of Cancer Drug Zaltrap After Sloan-Kettering Rejection

By ANDREW POLLACK In an unusual move, a big drug company said on Thursday that it would effectively cut in half the price of a new cancer drug after a leading cancer center said it ...

Pharmacy Board Chair Fired Over Compounding Flub

By Ed Silverman The scandal over the meningitis outbreak attributed to the New England Compounding Center took a new turn yesterday when Massachusetts state health officials fired ...
Page 3 of 9312345...102030...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS